Top Searches
Advertisement

Dr. Reddy's Powers Ahead: G V Prasad Reappointed, Dividend Announced, and Q4 Beats Estimates


Updated: May 09, 2025 16:52

Image Source: Moneycontrol
Dr. Reddy's Laboratories has posted a stellar Q4 FY25 set of results, highlighting its resilience and growth in the global pharma space. The board of the company has reappointed G V Prasad as Co-Chairman and Managing Director, guaranteeing leadership continuity at a critical juncture. Prasad's strategic vision has been the key to Dr. Reddy's global expansion and innovation-led growth.
 
Key Highlights:
  • Leadership Renewal: Reappointment of G V Prasad as Co-Chairman & MD ensures the leadership pipeline of the company, instilling faith among stakeholders and investors.
  • Dividend Declaration: The board has proposed a dividend of ₹8 per share for the year FY25, rewarding the shareholders and demonstrating strong cash generation. Ex-dividend date is July 16, 2025, and payment date is August 2, 2025.
  • Financial Beat: Dr. Reddy's posted consolidated Q4 revenue from operations of ₹85.28 billion, exceeding IBES estimates of ₹83.96 billion. Net profit jumped to ₹15.93 billion, ahead of expectations of ₹14.91 billion, boosted by US generics sales, new product launches, and operational efficiencies.
  • Growth Drivers: The quarter's performance was driven by successful absorption of acquisitions such as Nicotinell, growth in the vaccine portfolio, and strong sales of top products including gRevlimid in the US. Enhanced EBITDA margins and cost rationalization further contributed to the bottom line.
  • Analyst View: Market observers commend Dr. Reddy's emphasis on innovation, cost management, and global collaborations, and anticipate these drivers to continue momentum in future quarters.
With good leadership, shareholder-friendly dividend, and sound financials, Dr. Reddy's is set to grow and create value in the future.
 
Sources: Moneycontrol, Goodreturns, Investing.com

Advertisement

STORIES YOU MAY LIKE

Advertisement

Advertisement